Changes included the following: • Expanded the description of Maintenance Phase dosing for IP to prevent confusion of the dosing regimens. • Updated details of collection of RVVC history for subjects in the United States only. • Clarified that the countries of Romania and Ukraine would not enroll subjects <18 years of age. • Added Romania and Ukraine to list of countries where subjects <18 years of age could not be enrolled. • Clarified subject population eligible for enrollment as post-menarcheal (this was previously assumed). • Established RVVC history to be based on locally approved testing, as outlined in the study design. • Improved clarity on timelines for Papanicolaou test requirement. • Clarified definition of abstinence and restricted contraceptive methods to only highly effective methods during repeat dosing of fluconazole. • Added a cross-reference to allowed treatment plan should a subject fail to respond to fluconazole treatment for an acute VVC episode. • Added collunarium/nasal to list of concomitant steroids permitted and to Exclusion Criterion #5. • Reduced potential confounding factors for efficacy assessments. • Improved clarity for which pregnancy testing (central serum or local urine) would be performed at each visit. • Implemented testing request to evaluate cholesterol and triglycerides across all subject populations. • Clarified Informed Consent Form and included assent for subjects aged 12 to 17 years. • Clarified which bacterial testing would be performed locally and centrally. • Provided clarification on capsule formulation of oteseconazole. • Clarified subjects can be eligible for re-screening once. • Modified the protocol deviation criterion for IP compliance. • Implemented changes made during European Union Voluntary Harmonisation Procedure review as they were beneficial to subject safety and data quality from a global perspective.